Novo Introduces New Type 2 Medication

| Jul 1, 1998

Novo Nordisk Pharmaceuticals has introduced a new oral antidiabetic agent called Prandin (repaglinide). The medication is intended for people with type 2 diabetes, who are unable to satisfactorily control their hyperglycemia through diet and exercise. It can also be used in combination with metformin, which works with Prandin to control blood sugars.

Prandin stimulates the beta cells in the pancreas to secrete more insulin. It is taken orally as a tablet at mealtimes and works quickly and for a very short period of time. This helps patients manage their glucose load during meals, a key factor in the control of type 2 diabetes.

Although Prandin shows promise, it is not for everyone. Wendell Cheatham, MD, medical director of Novo Nordisk Pharmaceuticals, Inc., explains, "For many individuals with type 2 diabetes, insulin is still the appropriate therapy." He also notes that Prandin is not intended for type 1 patients, as it cannot restore their beta cell function.

Prandin does interact with some drugs that treat fungal and bacterial infections and troglitazone (a diabetes pill). Prandin may also cause low-glucose reactions, particularly if used with other drugs that lower glucose levels. Studies are currently underway to evaluate use of Prandin in combination with other drugs.

Click Here To View Or Post Comments

Categories: Blood Sugar, Diabetes, Insulin, Novo Nordisk, Type 2 Issues, Type 2 Medications

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.